JAK Inhibitors

Questions discussed in this category

Do patient co-morbidities impact when you prescribe oral jak inhibitors?

Are you less likely to prescribe it for patients with dyslipidemia or autoimmune disease?

What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?

How do you approach monitoring when using combination JAK inhibitors and methotrexate in RA?

Do you have concerns with the use of oral contraceptives in patients on JAK inhibitors given the black box warning for thromboembolic events?

How has this impacted your counseling and management?

2 Answers available

Can JAK inhibitors for established rheumatoid arthritis be continued when starting an immune checkpoint inhibitor?

2 Answers available

How would you approach the use of JAK inhibitors in a patient with stable RA who is now starting treatment for pulmonary MAC infection?

Patient previously failed abatacept and Rituximab.

1 Answer available

Would you be comfortable using a JAK inhibitor in a patient with baseline thrombocytosis?

Would the etiology of the thrombocytosis play a role in your decision-making?

1 Answer available

Do you ever consider using a higher dose of upadacitinib (30 mg daily) for rheumatoid arthritis in patients who fail to respond/partially respond to established dosing of 15 mg daily?

1 Answer available

How do you approach steroid-refractory GVHD in patients who either cannot receive ruxolitinib or do not respond to ruxolitinib?

1 Answer available

Should JAK inhibitors and anti-IL6 medications be avoided in patients with known diverticulosis?

2 Answers available

Papers discussed in this category

Arthritis & rheumatology (Hoboken, N.J.), 2016-11

Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.

Annals of the rheumatic diseases, 2019-04

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.

Journal for immunotherapy of cancer, 2022 Jan

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition.

Clinical rheumatology, 2020 Sep 28

Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?

Frontiers in immunology, 2022 Sep 15

Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib.

Cancer cell, 2022 May 09

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.

Annals of the rheumatic diseases, 2023 May 29

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.

Arthritis & rheumatology (Hoboken, N.J.), 2017-03

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.

Annals of the rheumatic diseases, 2019 Jul 30

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.

N Engl J Med,

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

Autoimmunity reviews, 2023 Dec 20

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.

JAK Inhibitors

Questions discussed in this category

Papers discussed in this category

Related Topics